Skip to content
CharitiesAidWelfare, Medical Health Aged Care

Leading Haematologist Professor John Seymour AM joins Leukaemia Foundation Board

Leukaemia Foundation 3 mins read

The Leukaemia Foundation is delighted to announce the appointment of Professor John Seymour to its Board, effective immediately.

With more than three decades of world-class leadership in haematology, research and patient care, Professor Seymour brings exceptional clinical and translational expertise to the Leukaemia Foundation Board – a major asset as we work to accelerate progress in blood cancer treatment, care and outcomes.

Professor Seymour is an internationally recognised haematologist who until recently led the Haematology Department at the Peter MacCallum Cancer Centre and Royal Melbourne Hospital.

Holding MBBS, FRACP, PhD and fellowship of the Australian Academy of Health and Medical Sciences (FAHMS), Professor Seymour continues to contribute as an Honorary Professorial Fellow at the University of Melbourne Department of Medicine.

He also co-chaired Australia’s National Blood Cancer Taskforce alongside Leukaemia Foundation CEO, Chris Tanti, and in 2015 was appointed a Member of the Order of Australia (AM) for his significant service to haematology.

Professor Seymour’s career reflects a deep commitment to patient-centred care, equitable access to world-class treatment, and translating research discoveries into real-world outcomes.

As a new member of the Leukaemia Foundation Board, Professor Seymour will play a pivotal role in helping guide the organisations strategic direction, whilst driving innovation, improving care and treatment standards and ensuring every Australian diagnosed with a blood cancer receives the best possible chance of survival and quality of life.

“We are deeply honoured to welcome Professor Seymour to the Leukaemia Foundation Board,” said Lucio Di Giallonardo, Leukaemia Foundation Board Chair.

“His expertise, clinical insight, research leadership and dedication to equitable care will be fundamental as we intensify our mission to transform blood cancer outcomes for all Australians.”

With blood cancer incidence and mortality on track to be the leading cancer in Australia by 2035, Professor Seymour’s appointment comes at a crucial time. 

“Blood cancer incidence is rising, and more Australians than ever are living with the disease and its long-term impacts,” said Mr Di Giallonardo.

“Strong leadership and insights are therefore critical to improve patient outcomes and close the gaps in access to the best treatment and care across Australia.”

With Professor Seymour’s guidance, the Leukaemia Foundation will be even better positioned to:

  • Accelerate translation of cutting-edge research into standard clinical practice;
  • Advocate for equitable access to advanced treatments and support services regardless of where people live;
  • Strengthen collaboration with clinicians, researchers and policymakers to improve care, early diagnosis, survivorship and long-term outcomes;
  • Ensure the Leukaemia Foundation remains at the forefront of innovation and patient-centred care for all blood cancer types.

“Professor Seymour’s seat at our Board strengthens our mission to ensure that no Australian faces blood cancer alone,” added Mr Di Giallonardo.

“We are determined to accelerate progress to save lives, improve care, and give every person affected by blood cancer in this country, hope and support when they need it most.”

For more information on Professor Seymour and the Leukaemia Foundation Board visit leukeamia.org.au.

-END-


About us:

About the Leukaemia Foundation: The Leukaemia Foundation stands with Australia to help cure and conquer blood cancer – with care. Together we are attacking every blood cancer, from every direction, in every way we can. We stand beside every Australian to be their voice and their someone-to-turn to, fighting to get them access to the best care. We also accelerate research that is delivering rapid advancements in blood cancer diagnosis and treatments. Plus, we provide services and support that empower people living with any blood cancer to live well after diagnosis. You can learn more about the Leukaemia Foundation and blood cancer at leukaemia.org.au


Contact details:

Please contact the Leukaemia Foundation media team at [email protected] or call 0473 154 079. 

More from this category

  • Medical Health Aged Care
  • 19/12/2025
  • 09:05
Royal Australian College of GPs

RACGP celebrates WA excellence in general practice at awards

The Royal Australian College of General Practitioners (RACGP) WA Faculty has honoured outstanding contributions to general practice at its annual awards ceremony, celebrating leaders, educators, registrars, and practices across the state. The evening provided the opportunity to celebrate the College’s highest honour, the Rose-Hunt Award, awarded during GP25, which was presented to WA GP, Adjunct Associate Professor Frank R Jones, recognising his 45 years of service to general practice, including 40 years at Murray Medical Centre in Mandurah. Professor Jones has worked across rural, procedural, and community settings and held numerous leadership roles within the RACGP, including President, Vice President,…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 22:11
BeOne Medicines Ltd.

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancer FDA Fast Track Designation reflects the…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 19:11
Takeda Pharmaceutical Company Limited

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.